Arrowhead Research | ARWR - Sales Revenues

Stock Price
73.46
Daily Change
2.93 4.15%
Monthly
17.16%
Yearly
423.22%
Q2 Forecast
72.33

Arrowhead Research reported $264.03M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
Agios Pharmaceuticals USD 18.8M 1.17M Mar/2026
Alnylam Pharmaceuticals USD 1.17B 70M Mar/2026
Anika Therapeutics USD 30.62M 2.8M Dec/2025
Arrowhead Research USD 264.03M 7.56M Dec/2025
Heron Therapeutics USD 40.59M 2.38M Dec/2025
Incyte USD 1.27B 240M Mar/2026
Ionis Pharmaceuticals USD 246M 43M Mar/2026
Ligand Pharmaceuticals USD 59.66M 55.8M Dec/2025
Merck USD 16.29B 110M Mar/2026
Moderna USD 678M 342M Dec/2025
Nektar Therapeutics USD 21.81M 2.32M Dec/2025
Novartis USD 13.11B 226M Mar/2026
Sarepta Therapeutics USD 442.9M 43.5M Dec/2025
TG Therapeutics USD 192.57M 30.87M Dec/2025
Ultragenyx Pharmaceutical USD 207M 47M Dec/2025
Vertex Pharmaceuticals USD 3.19B 110M Dec/2025
Xencor USD 28.24M 7.24M Dec/2025